Efficacy and Safety of Celecoxib Combined with JOINS in the Treatment of Degenerative Knee Osteoarthritis: Study Protocol of a Randomized Controlled Trial

Overview

Journal Ther Adv Musculoskelet Dis

Date 2021 Jul 15

PMID 34262619

Authors

Man Soo Kim

In Jun Koh

Yong Gyu Sung

Dong Chul Park

Sung Cheol Yang

Yong In

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study will be to investigate the therapeutic effect and safety of non-steroidal anti-inflammatory drugs (NSAIDs) along with symptomatic slow-acting drugs for the treatment of osteoarthritis (SYSADOA), JOINS tablets, for degenerative knee osteoarthritis (OA) treatment and to determine the analgesic and anti-inflammatory effects of the combination therapy. In addition, we will investigate whether JOINS treatment alone after NSAID and JOINS combination treatment is effective in relieving and maintaining knee OA symptoms.

Methods: This study will be a prospective, randomized, double-blind endpoint study design. All patients will be randomly assigned to either intervention (celecoxib+JOINS) or control (celecoxib+placebo) groups. In Part 1, the intervention group will be administered celecoxib once a day and JOINS three times a day for a total of 12 weeks. In the control group, celecoxib will be administered once a day and JOINS placebo three times a day for a total of 12 weeks. In Part 2, JOINS alone and JOINS placebo alone will be administered for an additional 24 weeks in both groups, respectively. The primary endpoint will be the amount of change during the 12 weeks as assessed using the Western Ontario and McMaster Universities Osteoarthritis Index total score compared with baseline. The secondary endpoint will be the amount of change at 1, 4, 12, 24, and 36 weeks from the baseline for pain visual analog scale, Brief Pain Inventory, Short Form Health Survey-36 and biomarkers.

Results: The trial was registered with Clinical-Trials.gov (NCT04718649). The clinical trial was also registered on Clinical Research Information Service (CRIS) with the trial registration number KCT0005742.

Conclusions: The combination treatment of the most commonly used SYSADOA drug, JOINS, and selective COX-2 inhibitor celecoxib as the representative NSAID for knee OA treatment, can be compared with celecoxib alone treatment to determine the safety or therapeutic effect.

References

Park Y, Ha C, Han C, Bin S, Kim H, Jung Y . A prospective, randomized, double-blind, multicenter comparative study on the safety and efficacy of Celecoxib and GCSB-5, dried extracts of six herbs, for the treatment of osteoarthritis of knee joint. J Ethnopharmacol. 2013; 149(3):816-24. DOI: 10.1016/j.jep.2013.08.008. View

Al-Dadah O, Shepstone L, Donell S . Proprioception deficiency in articular cartilage lesions of the knee. Knee Surg Relat Res. 2020; 32(1):25. PMC: 7251730. DOI: 10.1186/s43019-020-00042-7. View

Bellamy N, BUCHANAN W, Goldsmith C, Campbell J, Stitt L . Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988; 15(12):1833-40. View

Sheehy L, Felson D, Zhang Y, Niu J, Lam Y, Segal N . Does measurement of the anatomic axis consistently predict hip-knee-ankle angle (HKA) for knee alignment studies in osteoarthritis? Analysis of long limb radiographs from the multicenter osteoarthritis (MOST) study. Osteoarthritis Cartilage. 2010; 19(1):58-64. PMC: 3038654. DOI: 10.1016/j.joca.2010.09.011. View

Bolognese J, Schnitzer T, Ehrich E . Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement. Osteoarthritis Cartilage. 2003; 11(7):499-507. DOI: 10.1016/s1063-4584(03)00082-7. View

Makarowski W, Zhao W, Bevirt T, Recker D . Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage. 2002; 10(4):290-6. DOI: 10.1053/joca.2001.0510. View

Hartog A, Hougee S, Faber J, Sanders A, Zuurman C, Smit H . The multicomponent phytopharmaceutical SKI306X inhibits in vitro cartilage degradation and the production of inflammatory mediators. Phytomedicine. 2007; 15(5):313-20. DOI: 10.1016/j.phymed.2007.09.005. View

Anghel L, Farcas A, Oprean R . An overview of the common methods used to measure treatment adherence. Med Pharm Rep. 2019; 92(2):117-122. PMC: 6510353. DOI: 10.15386/mpr-1201. View

Valderrabano V, Steiger C . Treatment and Prevention of Osteoarthritis through Exercise and Sports. J Aging Res. 2010; 2011:374653. PMC: 3004403. DOI: 10.4061/2011/374653. View

10.

Choi J, Kim D, Yoon J, Youn H, Yi J, Ryu K . Effects of SKI 306X, a new herbal agent, on proteoglycan degradation in cartilage explant culture and collagenase-induced rabbit osteoarthritis model. Osteoarthritis Cartilage. 2002; 10(6):471-8. DOI: 10.1053/joca.2002.0526. View

11.

Lanyon P, OReilly S, Jones A, Doherty M . Radiographic assessment of symptomatic knee osteoarthritis in the community: definitions and normal joint space. Ann Rheum Dis. 1999; 57(10):595-601. PMC: 1752476. DOI: 10.1136/ard.57.10.595. View

12.

Clegg D, Reda D, Harris C, Klein M, ODell J, Hooper M . Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006; 354(8):795-808. DOI: 10.1056/NEJMoa052771. View

13.

Boswell D, Ostergaard K, Philipson R, Hodge R, Blum D, Brown J . Evaluation of GW406381 for treatment of osteoarthritis of the knee: two randomized, controlled studies. Medscape J Med. 2008; 10(11):259. PMC: 2605121. View

14.

Bang H, Ni L, Davis C . Assessment of blinding in clinical trials. Control Clin Trials. 2004; 25(2):143-56. DOI: 10.1016/j.cct.2003.10.016. View

15.

Hunter D, Bierma-Zeinstra S . Osteoarthritis. Lancet. 2019; 393(10182):1745-1759. DOI: 10.1016/S0140-6736(19)30417-9. View

16.

Bruyere O, Cooper C, Pelletier J, Branco J, Brandi M, Guillemin F . An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014; 44(3):253-63. DOI: 10.1016/j.semarthrit.2014.05.014. View

17.

Kamper S, Maher C, Mackay G . Global rating of change scales: a review of strengths and weaknesses and considerations for design. J Man Manip Ther. 2010; 17(3):163-70. PMC: 2762832. DOI: 10.1179/jmt.2009.17.3.163. View

18.

Selvan T, Rajiah K, Nainar M, Mathew E . A clinical study on glucosamine sulfate versus combination of glucosamine sulfate and NSAIDs in mild to moderate knee osteoarthritis. ScientificWorldJournal. 2012; 2012:902676. PMC: 3346693. DOI: 10.1100/2012/902676. View

19.

Wolfe M, Lichtenstein D, Singh G . Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999; 340(24):1888-99. DOI: 10.1056/NEJM199906173402407. View

20.

Park H, Cho S, Im S, Jung S, Kim D, Jang E . Treatment patterns of knee osteoarthritis patients in Korea. Korean J Intern Med. 2018; 34(5):1145-1153. PMC: 6718767. DOI: 10.3904/kjim.2017.304. View